Trends in cervical intra-epithelial neoplasia in Iceland through 1995: Evaluation of targeted age groups and screening intervals

Acta Obstetricia et Gynecologica Scandinavica

Volumn 78, Issue 6, 1999, Pages 486-492

  Sigurdsson, Kristjan ^a  

^a ICELANDIC CANCER SOCIETY   (Iceland)

Author keywords

Cytologic lesions; Histologic lesions; Invasive disease; Smear tests

Indexed keywords

ADULT; AGE; AGED; ARTICLE; CANCER GRADING; CANCER SCREENING; FEMALE; HUMAN; ICELAND; PAPANICOLAOU TEST; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; UTERINE CERVIX CARCINOMA IN SITU;

EID: 0032986083     PISSN: 00016349     EISSN: None     Source Type: Journal    
DOI: 10.1080/j.1600-0412.1999.780603.x     Document Type: Article

References (41)

1. Hakama M. A screening programme that worked: Discussion paper. J R Soc Med 1990; 83: 322-4.
2. Sigurdsson K. Effect of organized screening on the risk of cervical cancer. Evaluation of screening activity in Iceland, 1964-1991. Int J Cancer 1993; 54: 563-70.
3. Villa LL. Human papillomaviruses and cervical cancer. Cancer Res 1997; 71: 321-41.
4. Becker TM, Stonc KM, Alexander ER. Genital human papillomavirus infection. A growing concern. Obstet Gynecol Clin North Am 1987; 14: 389-96.
5. Chuang T-Y, Perry HO, Kurland LT, Ilstrup DM. Condyloma accuminatum in Rochester, Minn., 1950-1978. I. Epidemiology and clinical features. Arch Dermatol 1984; 120: 469-75.
6. Sigurdsson K, Adalsteinsson S, Tulinius H, Ragnarsson J. The value of screening as an approach to cervical cancer control in Iceland, 1964-1986. Int J Cancer 1989; 43: 1-5.
7. Papanicolau GN. A survey of the actualities and potentialities of exfoliative cytology in cancer diagnosis. Ann Med 1948; 30: 661-74.
8. Koss LG. Current concepts of intraepithelial neoplasia in the uterine cervix. Appl Pathol 1987; 5: 7-18.
9. Richart RM. Cervical intraepithelial neoplasia. In: Sommers SC, ed. Pathology Annual. New York: Appleton-Century-Crofts 1973: 301-28.
10. Boyes DA, Morrison B, Knox EG, Draper G, Miller AB. A cohort study of cervical cancer screening in British Columbia. Clin Invest Med 1982; 5: 1-29.
11. Miller AB, Knight J, Narod S. The natural history of cancer of the cervix and the implications for screening policy. In: Miller AB, Chamberlain J, Day NE, Hakama M, Prorok PC, eds. Cancer Screening. Cambridge, UK: Cambridge University Press, 1991: 141-52.
12. Schenck U, Herbert A, Solomon D, Amma NS, Collins RJ, Gupta SK et al. Terminology. IAC task force summary. Acta Cytol 1998; 42: 5-15.
13. Solomon D, Frable WJ, Vooijs GP, Wilbur DC, Amma NS, Collins RJ et al. ASCUS and AGUS criteria. IAC task force summary. Acta Cytol 1998; 42: 16-24.
14. Kivat NB, Keutsky LA. Do our current cervical cancer control strategies still make sense? J Natl Cancer Inst 1996; 88: 317-18.
15. Richart RM, Masood S, Syrjänen KJ, Vassilakos P, Kaufman RH, Meisels A et al. Human papillomavirus. IAC task force summary. Acta Cytol 1998; 42: 50-8.
16. Jenkins D, Sherlaw-Johnson C, Gallivan S. Can papilloma virus testing be used to improve cervical cancer screening? Int J Cancer 1996; 65: 768-73.
17. Sigurdsson K, Árnadottir Th, Snorradottir M, Benediktsdottir K, Saemundsson H. Haman papillomavirus (HPV) in an Icelandic population: The role of HPV DNA testing based on hybrid capture and PCR assays among women with screen-detected abnormal Pap smears. Int J Cancer 1997; 72: 446-52.
18. Miller AB, Chamberlain J, Day NE, Hakama M, Prorok PC. Report on working of the UICC project on evaluation of screening for cancer. Int J Cancer 1990; 46: 761-9.
19. Coleman D, Day N, Douglas G, Farmery E, Lynge E, Philip J et al. European guidelines for quality assurance in cervical cancer screening. Europe Against Cancer Programme. Eur J Cancer 1993; 29A: (suppl.4) S1-38.
20. Day NE. Screening for cancer of the cervix. J Epidemiol Community Health 1989; 43: 103-6.
21. Cole P, Morrison AS. Basic issues in cancer screening. In: Miller AB, ed. Screening in Cancer. UICC Tech Rep Ser 1978; 40: 7-39.
22. Anonymous. IARC Working Group on Evaluation of Cervical Cancer Screening Programmes. Screening for squamous cervical cancer: The duration of low risk after negative result of cervical cytology and its implication for screening policies. Br Med J 1986; 293: 659-64.
23. Sigurdsson K. Quality assurance in cervical cancer screening: The Icelandic experience 1964-1993. Eur J Cancer 1995; 31A: 728-34.
24. Sigurdsson K, Benediktsdottir K, Snorradottir M, Saemundsson H, Olafsson J, Einarsson GV. Cervical intra-epithelial neoplasia and koilocytotic lesions of the lower genitalia in an Icelandic population. Int J Gynecol Cancer 1991; 1: 49-57.
25. Hakama M. Effect of population screening for carcinoma of the uterine cervix in Finland. Maturitas 1985; 7: 3-10.
26. Chamberlain J. Reasons that some screening programmes fail to control cervical cancer. In: Hakama M, Miller AB, Day NE, eds. Screening for Cancer of the Uterine Cervix. IARC Sci Publ 1986; 76: 161-8.
27. Falcone T, Ferenczy A. Cervical intra-epithelial neoplasia and condyloma: An analysis of diagnostic accuracy of post-treatment follow-up methods. Am J Obstet Gynecol 1986; 154: 260-4.
28. Richart RM, Wright TC. Controversies in the management of low-grade cervical intraepithelial neoplasia. Cancer 1993; 71: 1413-21.
29. Lonky MN, Navarre LG, Saunders S, Sadeghi M, Wolde-Tsadik G. Low-grade Papanicolaou smears and the Bethesda system: A prospective cytohistopathologic analysis. Obstet Gynecol 1995; 85: 716-20.
30. Schiffman MH, Bauer HM, Hoover RN, Glass AG, Cadell DM, Rush BB et al. Epidemiological evidence showing that human papillomavirus infection causes most cervical intra-epithelial neoplasia. J Natl Cancer Inst 1993; 85: 958-64.
31. Bosch FX, Manos MM, Muñoz N, Sherman M, Jansen AM, Peto J et al. Prevalence of human papillomavirus in cervical cancer: A worldwide perspective. J Nat Cancer Inst 1995; 87: 796-802.
32. Schiffman MH. Latest HPV findings: Some clinical implications. Contemp OB/GYN 1993; 38: 27-40.
33. Ferenczy A. Viral testing for genital human papillomavirus infections: Recent progress and clinical potentials. Int J Gynecol Cancer 1995; 5: 321-8.
34. Anonymous. National Cancer Institute Workshop. The 1988 Bethesda system for reporting cervical/vaginal cytologic diagnoses. JAMA 1989; 262: 931-4.
35. Sigurdsson K, Árnadottir Th, Snorradottir M, Benediktsdottir K, Saemundsson H. Human papillomavirus (HPV) in an Icelandic population: Correlation of HPV DNA to cyto- and histopathologic lesions and evaluation of treatment strategies. Int J Gynecol Cancer 1996; 6: 175-82.
36. Campion MJ, McCance DJ, Cuzick J, Singer A. Progressive potential of mild cervical atypia: A prospective cytological colposcopic and virological study. Lancet 1986; ii: 237-40.
37. Sigurdsson K, Sigfússon BF. Cancer Screening in Iceland 1996. Reykjavík: Icelandic Cancer Society, 1997: 13-16.
38. Sigurdsson K. The Icelandic and Nordic cervical screening programs: Trends in incidence and mortality rates through 1995. Acta Obstet Gynecol Scand 1999; 78: 478-85.
39. Hakulinen T, Andersen A, Malker B, Pukkala E, Schou G, Tulinius H. Trends in cancer incidence in the Nordic countries. Acta Pathol Microbiol Immunol Scand Sect A 1986; 94: 1-151 (suppl 288).
40. Hakama M, Magnus K, Pettersson F, Storm H, Tulinius H. Effect of organized screening on the risk of cervical cancer in the Nordic countries. In: Miller AB, Chamberlain J, Day NE, Hakama M, Prorok PC, eds. Cancer Screening. Published for UICC, Geneva. Cambridge: Cambridge University Press, 1991: 153-62.
41. Cruickshank ME, Angus V, Kelly M, McPhee S, Kitchener HC. The case for stopping cervical screening at age 50. Br J Obstet Gynaecol 1997; 104: 586-9.